Physician profile

Michael Wong

Los Angeles, CA

NPI 1093906836

$510.31

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$194.21
Education$64.54

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Integra Lifesciences Corporation $99.25 2023 Durasorb Monofilament Mesh
Sientra, INC. $90.16 2022
Extremity Medical $83.33 2022
Novo Nordisk INC $64.54 2023 Ozempic
Janssen Pharmaceuticals, INC $56.57 2023 Xarelto
Esperion Therapeutics, INC. $30.75 2020
Biotronik INC. $25.66 2022
Abbott Laboratories $21.66 2019
Lilly USA, LLC $19.96 2023 Mounjaro, Trulicity
Medtronic, INC. $18.43 2024 Intellis Adaptivestim

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Michael Wong

$510.31

in general payments reported 2019-2025

Years
2019-2024
Top company
Integra Lifesciences Corporation

https://glasscript.com/doctor/4840/michael-wong

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.